Classification_NN
of_IN
IVS1-10T_NN
--_:
&gt;_JJR
C_NN
as_IN
a_DT
polymorphism_NN
of_IN
BRCA1_NN
._.

Mutations_NNS
inactivating_VBG
the_DT
tumor_NN
suppressor_NN
gene_NN
BRCA1_NN
may_MD
be_VB
responsible_JJ
for_IN
disease_NN
for_IN
up_RB
to_TO
80_CD
%_NN
of_IN
familial_JJ
ovarian_JJ
cancer_NN
cases_NNS
._.

In_IN
this_DT
syndrome_NN
,_,
tumorigenesis_NN
classically_RB
initiates_VBZ
from_IN
an_DT
inherited_VBN
mutation_NN
in_IN
one_CD
allele_NN
followed_VBN
by_IN
somatic_JJ
deletion_NN
of_IN
the_DT
normal_JJ
allele_NN
._.

Sequencing_NN
of_IN
BRCA1_NN
amplified_VBN
from_IN
genomic_JJ
DNA_NN
of_IN
lymphocytes_NNS
and_CC
microdissected_VBN
ovarian_JJ
tumor_NN
cells_NNS
of_IN
a_DT
familial_JJ
ovarian_JJ
cancer_NN
patient_NN
revealed_VBD
three_CD
,_,
rare_JJ
heterozygous_NN
DNA_NN
variations_NNS
-LRB-_-LRB-
2418delA_NN
,_,
233G_NN
--_:
&gt;_JJR
A_NN
,_,
and_CC
IVS1-10T_NN
--_:
&gt;_JJR
C_NN
-RRB-_-RRB-
in_IN
both_CC
tumor_NN
and_CC
constitutional_JJ
-LRB-_-LRB-
lymphocyte_NN
-RRB-_-RRB-
DNA_NN
._.

Thus_RB
,_,
both_DT
copies_NNS
of_IN
BRCA1_NN
were_VBD
retained_VBN
in_IN
tumor_NN
._.

Haplotype_NN
analysis_NN
of_IN
the_DT
patient_NN
and_CC
four_CD
siblings_NNS
assigned_VBD
2418delA_NN
to_TO
one_CD
copy_NN
of_IN
BRCA1_NN
and_CC
233G_NN
--_:
&gt;_JJ
A_NN
and_CC
IVS1-10T_NN
--_:
&gt;_JJ
C_NN
to_TO
the_DT
other_JJ
._.

The_DT
DNA_NN
change_NN
,_,
2418delA_NN
,_,
is_VBZ
considered_VBN
a_DT
mutation_NN
that_WDT
inactivated_VBD
one_CD
BRCA1_NN
allele_NN
because_IN
it_PRP
caused_VBD
a_DT
frameshift_NN
and_CC
generation_NN
of_IN
a_DT
premature_JJ
stop_NN
codon_NN
,_,
resulting_VBG
in_IN
synthesis_NN
of_IN
a_DT
truncated_VBN
peptide_NN
as_RB
evidenced_VBN
by_IN
an_DT
in_FW
vitro_FW
protein_NN
truncation_NN
test_NN
._.

The_DT
DNA_NN
variation_NN
,_,
233G_NN
--_:
&gt;_JJ
A_NN
,_,
does_VBZ
not_RB
result_VB
in_IN
an_DT
amino_NN
acid_NN
change_NN
,_,
and_CC
is_VBZ
considered_VBN
a_DT
benign_JJ
polymorphism_NN
._.

IVS1-10T_NN
--_:
&gt;_JJ
C_NN
is_VBZ
a_DT
unique_JJ
BRCA1_NN
change_NN
that_WDT
occurs_VBZ
in_IN
the_DT
last_JJ
nucleotide_NN
of_IN
a_DT
consensus_NN
sequence_NN
for_IN
a_DT
branch_NN
site_NN
critical_JJ
for_IN
RNA_NN
splicing_NN
._.

Therefore_RB
,_,
we_PRP
investigated_VBD
whether_IN
IVS1-10T_NN
--_:
&gt;_JJR
C_NN
deleteriously_RB
affected_VBD
BRCA1_NN
splicing_NN
or_CC
expression_NN
,_,
and_CC
thereby_RB
inactivated_VBD
the_DT
other_JJ
BRCA1_NN
allele_NN
._.

Using_VBG
the_DT
technique_NN
of_IN
reverse_JJ
transcription-polymerase_NN
chain_NN
reaction_NN
-LRB-_-LRB-
PCR_NN
-RRB-_-RRB-
with_IN
RNA_NN
isolated_VBN
from_IN
lymphoid_JJ
cell_NN
lines_NNS
of_IN
the_DT
patient_NN
and_CC
of_IN
controls_NNS
,_,
no_DT
evidence_NN
was_VBD
found_VBN
that_IN
IVS1-10TC_NN
abnormally_RB
disrupted_VBD
mRNA_NN
splicing_NN
or_CC
caused_VBD
the_DT
absence_NN
of_IN
BRCA1_NN
mRNA_NN
._.

Thus_RB
,_,
IVS1-10T_NN
--_:
&gt;_JJR
C_NN
is_VBZ
not_RB
harmful_JJ
to_TO
BRCA1_NN
function_NN
,_,
and_CC
is_VBZ
classified_VBN
a_DT
benign_JJ
polymorphism_NN
._.

Retention_NN
of_IN
the_DT
normal_JJ
BRCA1_NN
allele_NN
in_IN
the_DT
tumor_NN
with_IN
the_DT
heterozygous_JJ
germline_NN
BRCA1_NN
mutation_NN
,_,
2418delA_NN
,_,
indicated_VBD
that_IN
mutational_JJ
inactivation_NN
of_IN
both_DT
BRCA1_NN
alleles_NNS
was_VBD
not_RB
required_VBN
for_IN
tumorigenesis_NN
._.

It_PRP
is_VBZ
possible_JJ
that_IN
the_DT
normal_JJ
allele_NN
may_MD
be_VB
functionally_RB
inactivated_VBN
by_IN
a_DT
nonmutational_JJ
mechanism_NN
._.

